Second-line chemotherapy rechallenge in lung cancer patients: a Moroccan real-world study
At progression during or after first-line chemotherapy plus platinum, re-challenging single-agent chemotherapy in monotherapy or erlotinib did not offer modest activity in the Moroccan population.
Authors
- Ismail Essâdi (ORCID: https://orcid.org/0000-0002-3355-3790)
- Farah Choulli (ORCID: https://orcid.org/0000-0002-5789-6288)
- Hassan Abdelilah Tafenzi
- Rhizlane Belbaraka
Institutions
- Cadi Ayyad University (MA)
- Centre Hospitalier Universitaire Mohammed VI (MA)
- Hôpital Militaire Avicenne (MA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3389/fonc.2025.1489327
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00